18th Jun 2024 18:47
Destiny Pharma PLC - biotechnology company, focused on developing and commercialising medicines for life-threatening infections - Announces new data on one of its XF Drug Platform compounds, XF-70, which has demonstrated potency in an in vivo model of ringworm, a common fungal skin infection. Says ringworm affects up to one in four people worldwide. XF-70 is a member of a novel class of antimicrobial drugs. Says drug has been shown "to have a rapid bactericidal activity even within biofilms, and is structurally related to the company's leading drug, XF-73 which is being developed for the prevention of post-surgical staphylococcal infections." Read More
